uploads/2018/03/Cosentyx.png

How Is Novartis’s Cosentyx Positioned after 4Q17?

By

Updated

Cosentyx revenue trends

In 4Q17, Novartis’s (NVS) Cosentyx generated revenues of $615 million compared to $391 million in 4Q16, which reflected ~57% growth on a year-over-year (or YoY) basis and ~11% growth quarter-over-quarter. In fiscal 2017, Cosentyx generated revenues of $2.1 billion compared to $1.1 billion in 2016, which reflected ~84% growth on a YoY basis.

Solid growth for use across all indications for which Cosentyx has been approved led to the high revenue growth of the drug. Novartis estimated that around 125,000 patients have been treated with Cosentyx since its launch.

Article continues below advertisement

Recent developments

In February 2018, the US Food and Drug Administration (or FDA) approved a label expansion of Cosentyx for its use for the treatment of moderate-to-severe plaque psoriasis. The label update for Cosentyx was approved based on the results of the phase 3 scalp psoriasis trial. In the trial, Cosentyx demonstrated significant improvements in skin clearance in individuals with scalp psoriasis. According to the American Academy of Dermatology, ~60 million individuals worldwide are affected by scalp psoriasis. The label expansion of Cosentyx is expected to further boost the revenue growth.

In February 2018, Novartis presented additional results from the Sculpture trial. In the trial, two-thirds of individuals with moderate-to-severe plaque psoriasis treated with Cosentyx saw no impact of the skin disease on their quality of life over five years.

In the plaque psoriasis drugs market, Cosentyx competes with Celgene’s (CELG) Otezla, AbbVie’s (ABBV) Humira, Amgen’s (AMGN) Enbrel, and Johnson & Johnson’s (JNJ) Remicade.

Advertisement

More From Market Realist